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Abstract
Background. Given the ongoing opioid crisis in the United States (US), we investigated the
opioid situation in Europe. The aims of the study are to provide an overview of trends in
prescription opioid (PO) use and opioid-related adversities between 2010 and 2018 for different
opioids in 19 European countries and to present a comparison with similar data from the US.
Methods. A multisource database study with national data from 19 European countries
evaluating trends between 2010 and 2018 in (a) PO consumption, (b) high-risk (HR) opioid
users, (c) opioid-related hospital admissions, (d) opioid-related overdose deaths, (e) opioid use
disorder treatment entries, and (f) patients in opioid substitution therapy (OST). Within and
between-country comparisons and comparisons with data from the US were made.
Results. There was considerable variation between European countries. Most countries showed
increased PO consumption with the largest increase and the highest consumption in the United
Kingdom (UK) compared to the rest of Europe and the US in 2018 (UK: 58,088 defined daily
doses for statistical purposes/1000 population/day). In 2018, Scotland had the highest rates (per
100,000 population) ofHR opioid users (162), opioid-related hospital admissions (118), opioid-
related deaths (227), opioid use disorder treatment admissions (190), and OST patients (555) of
all included European countries. These rates were similar or even higher than those in the US in
2018. Other countries with high rates of opioid-related adversities were Northern Ireland
(synthetic and “other” opioids), Ireland (heroin and methadone), and England (all opioids).
All other countries had no or little increase in opioid-related adversities.
Conclusions. Apart from the British Isles and especially Scotland, there is no indication of an
opioid crisis comparable to that in the US in the 19 European countries that were part of this
study.More research is needed to identify drivers and develop interventions to stop the emerging
opioid crisis in the UK and Ireland.
Introduction
The opioid crisis in the United States
The United States (US) is currently facing a serious “opioid crisis” with an increase in opioid-
related deaths between 2000 and 2018 from 3 to almost 15 per 100,000 population per year
[1]. The initial key driver of the crisis in the US was an increase in the use of prescription opioids
(POs). Between 1999 and 2010, the sales of POs quadrupled following the inclusion of pain as the
fifth vital sign, liberalization of laws governing POs, aggressive and misleading marketing by the
pharmaceutical industry, and the existence of so-called “pill mills” [2,3]. Policymakers in the US
responded to the opioid crisis with a national focus on reducing unnecessary prescribing, closing
“pill mills,” strengthening regulatory controls and increasing treatment facilities for patients with
opioid use disorders (OUD). However, opioid-relatedmortality continued to increase with a shift
from PO-related deaths to heroin-related deaths since 2010/2011 and to illicitly manufactured
fentanyl (IMF) related deaths since 2013/2014 [4–6].
The opioid situation in Europe
The opioid situation in Europe seems to be less problematic than in the US [3,7,8]. While the
number of opioid prescriptions has increased since 2009 [3], prescription rates are still much
lower in most European countries than in the US, and in some countries rates are stable or
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Addiction (EMCDDA), the number of opioid-related overdose
deaths was stable in Europe between 2007 and 2017 at approxi-
mately 1two opioid-related deaths per 100,000 population per year
[10]. Europe is, however, heterogeneous, with some countries such
as Scotland reporting a significantly higher opioid-relatedmortality
than others [11]. Furthermore, a substantial mortality risk has been
found for the nonmedical use of certain POs in some European
countries [12,13]. There is also evidence that synthetic opioids are
increasingly used by OUD patients seeking treatment [14].
Relevance and aim of this paper
While there are several published studies summarizing the opioid
situation in individual countries and some analyses of the European
situation, an up to date summary with good quality data that pro-
vides comparisons within and between European countries and with
theUS is lacking [8,12]. This has several reasons. First, it is difficult to
summarize already published literature due to the different param-
eters and methods that are used across countries. Second, relevant
data are not always published in peer-reviewed papers andonly exists
in the “gray literature.” Finally, the Europe-wide summaries that are
available, such as the annual EMCDDA reports, do not provide a
detailed analysis per European country with a breakdown per opioid
type [15,16]. This is unfortunate given the history of the opioid crisis
in the US and we believe that data on the different types of opioids is
essential for an effectivemonitoring of the opioid situation in Europe
and for the development of targeted prevention and treatment pro-
grams. This paper thus aims to provide an overview of trends in the
use of opioids and their adverse effects in Europe, using a novel
approach by sourcing data from national databases in several
European countries and providing separate data for the different
types of opioids. Data were collected on trends between 2010 and
2018 in the following outcomes: (a) PO consumption, (b) high-risk
(HR) opioid users, (c) opioid-related hospital admissions, (d) opioid-
related overdose deaths, (e) opioid use disorder (OUD) treatment
entries, and (f) patients in opioid substitution therapy (OST). These
data were used to study trends within the European countries and to
make comparisons with the US.
Methods
Design
Ecological study using national data from various national and
international databases with information on PO use and opioid-
related adversities between 2010 and 2018.
Definitions
To collect data and interpret the findings fromdifferent countries, it
is crucial to use clear definitions. Below we provide a short defini-
tion for the most relevant concepts and outcome measures.
Opioid crisis
Alarming situation related to opioid use, misuse, and/or opioid-
related health complications, for example, increased opioid-related
deaths, and treatment admissions and hospitalizations due to PO
and illicit opioid use.
Prescription opioids
Legally manufactured opioids that can be prescribed by medical pro-
fessionals mostly as analgesics or in the medical treatment of patients
with an OUD. POs can also, however, be diverted and used illegally.
Illicit opioids
Illicitly manufactured opioids, not prescribed by medical profes-
sionals and most often used recreationally or in the context of self-
medication of an OUD, including IMF and heroin.
Synthetic opioids
Man-made drugs (prescription and illicit) that mimic the effects of
natural opioids (such as morphine), including fentanyl, fentanyl
analogues, tramadol, methadone, and buprenorphine (semi-
synthetic).
HR opioid use
Defined by the EMCDDA as “recurrent drug use that is causing
actual harms to the person (including dependence, but also other
health, psychological, or social problems) or is placing the person at
a high probability/risk of suffering such harms (e.g., intense use of
substances or use of risky combinations and/or risky routes of
administration).” Estimates are mainly based on extrapolations
from existing records and registers using drug use related indicators
(e.g., treatment or mortality data) [17,18].
Defined daily dose for statistical purposes
Defined daily dose for statistical purposes. A technical measure-
ment unit to define PO consumption. S-DDD refers to the World
Health Organization (WHO) defined daily doses, that is, the
assumed average maintenance dose per day for a drug used for
its indication in adults [19]. The United Nations’ International
Narcotics Control Board (INCB) reports opioid consumption
in their annual Technical Reports in s-DDD using their own
conversion factor, which is generally in line with that of the
WHO [20].
Procedures and outcomes
A total of 36 European countries was contacted via the EMCDDA
Reitox National Focal Point network, the Correlation Focal Point
network, and personal contacts (Figure 1) [21,22]. Of these, 19 Euro-
pean countries provided sufficient data to be included in our analysis,
that is, with data for at least two of the following outcomes:
Outcome 1: Consumption of POs
The annual Technical Reports from the INCB were used to provide
data on the national consumption (in s-DDDper 1000 population per
day) of different PO’s in European countries and the US [20,23–26].
See Supplement A for a detailed description of this dataset and its
limitations.
Outcome 2: HR opioid users (most recent annual rate)
Data on the annual number of HR opioid users were taken from the
most recent annual EMCDDA country reports [27]. Because the
EMCDDA country reports did not cover Scotland or England, we
used data from regional reports for these two areas [28–30].
Outcomes 3–6
Where possible data were sourced according to the ninth or tenth
revision of the WHO International Classification of Diseases cod-
ing system: ICD-9 or ICD-10 (see Supplement B for relevant
definitions). Rates per 100,000 inhabitants (where possible aged
15 years and older, otherwise aged 15–64 years or entire popula-
tion) were calculated using population data sources per country
from online statistical office databases. See Supplement C for a
detailed explanation of the data.
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Outcome 3: Opioid-related hospital admissions
Slightly different definitions were used for “all opioid-related hos-
pital admissions” (see Supplement D). For the analysis with a
breakdown per opioid type, data on opioid poisoning admissions
per opioid were defined in all countries using the following ICD-10
codes: heroin T401, methadone T403, synthetic opioids (other
than methadone, such as tramadol, fentanyl, and fentanyl ana-
logues) T404. Poisoning admissions due to other opioids (such
as codeine, morphine, hydromorphone, oxycodone, and opium)
T400, and opium T402, were combined into one category (“other
opioids”).
Outcome 4: Opioid-related overdose deaths
Data were collected on overdose deaths due to all opioids, heroin
(often combined with morphine), methadone, buprenorphine,
oxycodone, and other synthetic opioids (fentanyl and tramadol).
Outcome 5: OUD treatment admissions
Data were collected on treatment admissions (incident case entries by
primary drug) due to all OUDs, and per specific OUD, including
heroin, methadone, buprenorphine, oxycodone, fentanyl, and trama-
dol, where available.Most countries followed the EMCDDATreatment
Demand IndexprotocolVersion30 fordata collection [31].Therewere
limitations to data coverage in many countries (see Supplement C).
Outcome 6: Patients in OST
Data on patients in OST (prevalent cases) were taken mainly from
the annual EMCDDA country reports and otherwise from national
sources in various European countries [27].
Statistical analysis
Because the data we collected concern nationwide population data
and thus do not rely on stochastic principles, it is not possible to
Total countries contacted (n = 35):
Albania, Austria, Belgium, Bulgaria,
Croaa, Cyprus, Czech Republic, Denmark,
Estonia, England & Wales, Finland,
France, Germany, Greece, Hungary,
Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Netherlands,
Northern Ireland, Norway, Poland,
Portugal, Romania, Russia, Scotland,
Slovakia, Slovenia, Spain, Sweden,
Switzerland, Turkey
No response (n = 14):
Bulgaria, Croaa, Denmark, Finland,
Greece, Hungary, Luxembourg, Malta,
Poland, Portugal, Romania, Spain,
Sweden, Turkey































































Countries included (n= 19)
Countries contacted via EMCDDA Reitox
Network (n = 29):
Austria, Belgium, Bulgaria, Croaa, Cyrus,
Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, the Netherlands,
Norway, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden, Turkey
Countries contacted via personal
contacts (n = 14):
Belgium, Bulgaria, France, Finland,
Greece, Lithuania, Latvia, Poland,
Russia, Slovenia, Spain, Denmark,
Portugal, the Netherlands, Hungary,
Northern Ireland
Countries contacted via Correlaon
Network (n = 32):
Albania, Austria, Belgium, Bosnia &
Herzegovina, Bulgaria, Croaa, Czech
Republic, Finland, France, Georgia,
Germany, Greece, Hungary, Ireland, Italy,
Latvia, Luxembourg, Montenegro,
Macedonia, the Netherlands, Norway,
Poland, Portugal, Romania, Russian
Federaon, Scotland, Serbia, Slovakia,
Spain, Sweden, Switzerland
Figure 1. Flow chart and map of participating European countries.
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compute variance or SE (the SE is by definition 0).We therefore did
not apply statistical testing or present our findings with p-values or
confidence intervals. The observed trends are simply whole popu-
lation observations (there was no sampling of a “study
population”). Moreover, the current paper focuses on robust within
country changes and between-country differences, whereas rela-
tively small variations and differences are not discussed because
many of the measures that were used were not completely compa-
rable over time or between countries. We therefore decided to use
visual inspection of the data with an explicit focus on robust and
policy relevant differences to identify signals of a possible opioid
crisis in Europe.
Results
The 19 European countries included in the analysis cover most
European regions except for central and eastern Europe and Turkey
(Figure 1). Table 1 summarizes the most recent findings for all
available outcomes in these 19 European countries and the US. The
text describes only the most relevant findings, that is, a brief
description of the countries with the highest risks (countries with
stable or low rates are thus not explicitlymentioned in the text). The
level of detail in the description per country is dependent on the
availability of data per country. For more details, the reader can
refer to the relevant figures and Table 1.

































Scotland – 2010: 93*
162 2017: 118 2010: 109 2010: 124 2011: 589




2016–2018: 58088 2010: 301
84 216% – – – 2017: 276
England – 2010: 30
72 2012: 33* 2018: 40 2010: 119
(Total population) 2018: 35 (England and
Wales)
2018: 84 –
Austria 2008–2010: 16315 2010: 13 2010: 42 2010: 279
2016–2018: 19867 2017: 16 2018: 33 2018: 326
63 22% (15–64 years) (15–64 years) – (15–64 years)
Ireland 2008–2010: 5946
2016–2018 7061 2010: 13 2010: 48 2010: 134 2010: 258
62 19% 2017: 18 2017: 79 2018: 104 2017: 273
Italy 2008–2010: 3553
2016–2018: 5083 2010: 3 2010: 03 2013: 35 2010: 200
60 43% 2017: 1 2018: 03 2018: 31 2018: 144
Latvia 2008–2010: 827
2016–2018: 2102 2014: 11 2014: 08 2014: 74 2010: 13
57 154% 2018: 11 2018: 08 2018: 81 2018: 42
France 2008–2010: 8827
2016–2018: 8011 *2010: 8 2010: 05 2014: 16 2010: 304
50 9% 2018: 10 2017: 07 2018: 17 2017: 337
Lithuania 2008–2010: 1127
2016–2018: 1445 2010: 5 2010: 09 2013: 76 2010: 25
39 28% 2018: 2 2018: 16 2017: 60 2018: 28



































2016–2018: 11949 2010: 50 2010: 153
27 30% – 2018: 56 – 2017: 176
Cyprus 2008–2010: 704 2011: 9
2016–2018: 1630 2010: 11 2011: 56 2018: 20
20 132% – 2018: 08 2018: 52 (Total
population)
Germany 2008–2010: 15314 2010: 6 2010: 03 2010: 40 2010:95
2016–2018: 21167 2017: 4 2016: 03 2018: 8 2018: 96





2016–2018: 6261 2010: 1 2010: 02 2010: 23 2010: 23
19 79% 2018: 1 2018: 02 2018: 15 2018: 26
The Netherlands 2008–2010: 6565
2016–2018: 14621 2010: 4 2010: 03 2010: 10 2010: 74
13 123% 2017: 10 2017: 09 2015: 6 2015: 37
Estonia 2008–2010: 706
2016–2018: 969 2010: 80 2010: 89
– 37% – 2015: 66 – 2018: 90
Northern Ireland – 2010: 53* 2010: 36 2010: 29 2010: 45
– 2018: 78 2017: 58 2016: 67 2017: 66
Switzerland 2008–2010: 11140
2016–2018: 16134 2012: 32* 2010: 22 2010: 227
– 45% 2018: 23 – 2018: 31 2018: 196
Slovakia 2008–2010: 2972
2016–2018: 5528 2010: 7* 2010: 02 2014: 54 2010: 13
– 86% 2918: 4 2018: 02 2018: 18 2017: 13
Russia 2008–2010: 85 2010: 61
2016–2018: 237 2017: 18
– 179% – – (Total population) –
Belgium 2008–2010: 22769 2010: 204
2016–2018: 20758 2010: 6 2010: 03 2015: 28 2017: 183
– 9% 2018: 9 2016: 02 2018: 22 (≥18 years)
The United
States
2008–2010: 18376 2010: 197* 2010: 68 2010: 143 2011:393
2016–2018: 17853 2017: 300 2018: 146 2017: 210 2017: 417




Note: –, no data available. Opioid-related hospital admissions: *same definition used to define data. If a different population sample (not 15 years and older) was used to calculate the rates this is
given in brackets following the data from that country.
Abbreviations: OST, opioid substitution therapy/treatment; PO, prescription opioids; S-DDD, defined daily dose for statistical purposes.
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Outcome 1: Trends in PO consumption 2010–2018
PO consumption data from the INCBwas available for 17 European
countries and the US (Figure 2).
Overall PO consumption
Apart from Belgium and France, all European countries demon-
strated increasing trends in PO consumption over the observa-
tion period (Figure 2). While the initial rate in the UK was lower
than in the US, the largest increasing trend in opioid consump-
tion was seen in the UK (216% in the last decade) resulting in the
highest consumption of POs compared to the rest of Europe and
the US in 2018 (58,088 s-DDD per 1000,000 population per day).
Belgium also had a high initially stable rate followed by a peak in
2014–2016 (46,296 s-DDD per 1000,000 population per day) and
then a decrease in 2016–2018. Other European countries with
consumption rates higher than the US were Germany (21,667
s-DDD per 1000,000 population per day in 2016/2018) and
Austria (19,876 s-DDD per 1000,000 population per day in
2016/2018).
Opioid-specific consumption
An increasing trend in buprenorphine consumption was observed
in Austria, Cyprus, the Czech Republic, Estonia, Germany, Ireland,
Latvia, theNetherlands, Norway, Slovakia, Switzerland, theUS, and
the UK (Supplement Figure S2b–e).
An increasing trend in fentanyl consumption was observed in
Austria, Belgium, Cyprus, the Czech Republic, Estonia, Germany,
Italy, Latvia, Lithuania, the Netherlands, Norway, Russia, Slovakia,
and the UK.
An increasing trend in morphine consumption was seen in
Austria, Estonia, Ireland, the Netherlands, Russia, and Switzerland.
An increasing trend in oxycodone consumption was seen in
Austria, Belgium, Cyprus, the Czech Republic, Estonia, France,
Germany, Ireland, Italy, Lithuania, the Netherlands, Norway,
Russia, Slovakia, and Switzerland.
Summary
The highest consumption of POs compared to the rest of Europe
and the US in 2018 was in the UK, where specifically an increasing
trend in buprenorphine and fentanyl consumption was seen
between 2008/2010 and 2016/2018.
Outcome 2: HR opioid users
A recent annual rate of HR opioid users was available for 14 Euro-
pean countries (Table 1). The highest rate was seen in Scotland
(16two per 1000 population 15–64 years old), followed by England
(7two per 1000 population 15–64 years old), and other European
countries (1.3–6.3 per 1000 population 15–64 years old).
Outcome 3: Trends in opioid-related hospital admissions
2010–2018
Total opioid-related hospital admissions in Europe and the US
Data were available from 16 countries, however different methods
and definitions limit Europe-wide comparisons (see Supplement
D) (Figure 3A). The US had the highest rates of opioid-related
hospital admissions between 2010 and 2017 (197 per 100,000
population in 2010, 300 in 2018). Within Europe, Scotland and
Northern Ireland had the highest total opioid-related hospital
admission rates and increasing trends over the observation period,
however the rates still remained lower than in the US (Scotland:
93 per 100,000 population in 2010, 118 in 2017; Northern Ireland:
57 per 100,000 population in 2010, 78 in 2018). Regarding trends in
other European countries, opioid-related hospital admission rates
in the Czech Republic, England, and Latvia remained stable. A
decreasing trend was seen in Italy, Germany, Slovakia and Switzer-
land, and an increasing trend in Austria, Belgium, France, Ireland,
and the Netherlands. While in Lithuania a decreasing trend was
observed, there was a sharp increase between 2011 and 2012 from
5 per 100,000 population to 15 per 100,000 population, followed by















































Figure 2. PO consumption. Different scales are used on the Y-axis. In the case ofmissing data, the available data pointswere connectedwith a line. The data presented in tables and
figures as 2008–2010 are from the 2011 INCB report, the data presented as 2010–2012 from the 2013 INCB report, 2012–2014 from 2015 INCB report, 2014–2016 from the 2017 INCB
report, and 2016–2018 from the 2019 INCB report.
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Opioid-related hospital admissions per opioid in Europe
Datawere available from 10 European countries (Figure 3B–E). The
highest rate of heroin poisoning admissions was in Scotland, with
an increasing trend since 2012 (71 per 100,000 population in 2010
vs. 104 in 2017). An increasing trend was also observed in North-
ern Ireland (20 per 100,000 population in 2010 vs. 65 in 2018), and
a smaller increase in England (26 per 100,000 population in 2012
vs. 40 in 2018). A high rate was also seen in Lithuania in 2012 (49
per 100,000 population) followed by a decrease (05 per 100,000
population in 2018).
The highest methadone poisoning hospital admission rate was in
Scotland (57 per 100,000 population in 2010 and 48 in 2017). In
Northern Ireland, a peak was observed in 2014 followed by a decrease
(24per 100,000population in2014 vs. 05 in 2018).Adecreasing trend
was seen in Belgium (20 per 100,000 population in 2010 vs. 14 in
2018) and England (14 per 100,000 population 2012 vs. 07 in 2018).
An increasing trend was seen in the Netherlands (07 per 100,000
population in 2010 vs. 11 in 2017), and France (05 per 100,000 in
2010 vs. 08 in 2018). Following peaks in 2010 and 2012 (11 per






















































































Figure 3. Opioid-related hospital admissions. Different scales are used on the Y-axis. In the case of missing data, the available data points were connected with a line. The Y-axis
refers to population age, for example, inhabitants aged ≥15 years. *Similar definition of data, all other countries different definitions (see Supplement D).
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The highest synthetic opioid poisoning admission rate was in
Northern Ireland, with a sharp increase between 2011 and 2013
from 10 to 155 per 100,000 population, followed by a gradual
decrease (11.7 per 100,000 population in 2018).High rates were also
observed in England, but with a decreasing trend (76 per 100,000
population in 2012 vs. 56 in 2018). An increasing trend was
observed in the Netherlands between 2011 and 2017 (00 vs. 29
per 100,000 population), and in Belgium (22 per 100,000 in 2016
vs. 27 in 2018).
The highest “other opioid” poisoning hospital admission rate was
in Northern Ireland (448 per 100,000 population in 2010, 403 in



































































Figure 3d: Synthec Opioid Poisoning Hospital Admissions 
Belgium England France Lithuania
The Netherlands Northern Ireland Scotland Switzerland
Figure 3. (Continued)
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population in 2012, 207 in 2018). An increasing trend was observed
in the Netherlands (33 per 100,000 population in 2010, 61 in 2018).
Summary
The highest rates of opioid-related hospital admissions were seen in
the US, followed by Scotland and Northern Ireland where much
higher rates were observed than in other European countries. In
Scotland poisonings mainly involved heroin and methadone,
whereas in Northern Ireland this was “other opioids,” synthetic
opioids and—increasingly–heroin. High rates of “other opioids,”
synthetic opioids and heroin poisonings were also seen in England.
Outcome 4: Trends in opioid-related overdose deaths 2010–
2018
Total opioid-related overdose deaths in Europe and the US
Data were available from 18 countries (Figure 4A). Within Europe
the highest mortality rates were in Scotland (109 per 100,000 in
2010 and 227 in 2018), where opioid-relatedmortality increased by
1086% and exceeded the opioid-related mortality in the US in
2018. High rates were also observed in Estonia with a peak in 2012
of 134 per 100,000 population followed by a decreasing trend (66
in 2015), Ireland with an increasing trend between 2010 and 2017
peaking at 79 per 100,000 population in 2017, Northern Ireland
with an increasing trend between 2010 and 2016 (36 per 100,000
population vs. 61) followed by a slight decrease in 2017 (58), and
Norway with a peak of 59 per 100,000 population in 2016 followed
by a decreasing trend (56 in 2018).
Overdose mortality per specific opioid in Europe and the US
Data were available from 14 countries (Figure 4B–F). The highest
heroin (and morphine) mortality rates were in Scotland where an
104% increase was seen over the 8-year period (58 per 100,000
population in 2010 vs. 119 in 2018), exceeding rates in theUS in the
same period (10 per 100,000 population in 2010, 47 in 2018).
The highest methadone mortality rates were also in Scotland
where a 207% increase was observed over the 9-year period (40 per
100,000 population in 2010 vs. 123 in 2018), again exceeding the
rates seen in the US (15 per 100,000 population in 2010, 09 in
2018). Rates in Ireland also exceeded those in the US (17 per
100,000 population in 2010, 25 in 2017).
The highest rate of synthetic opioidmortality within Europe was
in Estonia (fentanyl) where data were only available between 2016
and 2018 with a peak at 86 per 100,000 population in 2017,
followed by a steep decline in 2018 to 20 per 100,000 population.
Thus, the peak rate came close to the rates seen in the US in this
period (90 and 99 per 100,000 population in 2017 and 2018
respectively, fentanyl and tramadol grouped together). High rates
and an increasing trendwere also observed inNorthern Ireland (13
per 100,000 population in 2010 vs. 30 in 2018, fentanyl and
tramadol grouped together).
The highest rate of buprenorphinemortality within Europe was
in Scotland with a steep increase between 2010 and 2018 (01 per
100,000 population in 2010 vs. 20 in 2018).
The highest rate of oxycodone mortality within Europe was in
Northern Ireland with an increasing trend reaching 10 per 100,000
population in 2018. The rate did not reach the rate in the US in the
same period (38 per 100,000 population in 2018), however the US
data also included morphine and hydrocodone.
Summary
Scotland was a clear outlier, with more opioid-related overdose
deaths than in the US during the entire observation period. How-
ever, unlike in the US where synthetic opioids are currently the
leading cause of opioid-related deaths, a breakdown per opioid type











































in opioid-related mortality in Scotland. Apart from in Northern
Ireland, synthetic opioids did not appear to be currently problem-
atic in terms of mortality in Europe, despite a transient increase in
Estonia. Ireland warrants attention due to relatively high rates of
methadone overdose deaths.
Outcome 5: Trends in OUD treatment admissions 2010–2018
Total opioid treatment admissions in Europe and the US
Data were available from 17 countries (Figure 5A). Within Europe,
Ireland, and Scotland had the highest opioid treatment admission
rates with decreasing trends over the observation period (Ireland:
134 per 100,000 population in 2010, 104 per 100,000 population in
2018; Scotland: 124 per 100,000 population in 2010 and 85 in 2018).
However, these rates did not reach the extremely high and increas-
ing treatment rates in theUS (143 per 100,000 population in 2010 to
210 per 100,000 population in 2017).
Opioid treatment admissions per opioid in Europe and the US
Data were available from 12 countries (Figure 5B–E). Ireland had
the highest heroin admission rates which decreased from 1274 per



























































































Figure 4. Opioid-related overdose deaths. Different scales are used on the Y-axis. In the case of missing data, the available data points were connected with a line. The Y-axis refers
to population age, for example, inhabitants aged ≥15 years. *There were a number of underreporting issues (see Supplement C).
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2014, and then decreased again to 953 in 2018. Scotland and
England also had high heroin treatment admission rates, which
were rather stable over time (between 80 and 110 admissions per
100,000 population). The admission rates in the US were initially
lower than in the UK (2010: 872 per 100,000), but started to
increase from 2014 and reached an all-time high in 2018 (1379
per 100,000), which was substantially higher than the rates in
Ireland (99 per 100,000 population), Scotland (914 per 100,000),
and England (729 per 100,000 population) at that time.
Scotland, England, and Ireland initially demonstrated very high
methadone admission rates (2010: England 57, Scotland 45, Ire-
land 37 per 100,000 population), exceeding those in theUS (21 per
100,000 population in 2010). However, following a steep decrease
during the observation period, rates in England and Scotland were
similar to those in the rest of Europe and theUS (Scotland 2018: 28;
England 2018: 24; US 2017: 10 per 100,000 population). Rates in
Ireland, however, increased during the observation period, peaking
in 2015 at 87 per 100,000 population and then decreasing slightly
to 60 per 100,000 population in 2018. Other countries with rates
exceeding those in the US were Belgium (decreasing trend from 21
per 100,000 population in 2015 to 15 in 2018), Lithuania (increas-
ing trend from 11 per 100,000 population in 2013 to 28 in 2017),










































































Figure 4d: Other Synthec Opioid Overdose Mortality 
The Czech Republic (fentanyl & tramadol)
Estonia (fentanyl)
Germany^ (fentanyl)
Ireland (tramadol & fentanyl)
Lithuania (all synthec opioids)
Northern Ireland (fentanyl & tramadol)
Scotland (fentanyl & tramadol)
England & Wales (fentanyl & tramadol)
France (fentanyl & tramadol)
Italy (fentanyl)
Latvia (fentanyl & tramadol)
The Netherlands (all synthec opioids)
Norway (all synthec opioids)
The US (synthec opioids such as fentanyl & tramadol)
Figure 4. (Continued)
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Between 2010 and 2015 there was a steep increase in bupre-
norphine admissions in Scotland (70 per 100,000 population in
2015) followed by a gradual decline, but rates remained higher
than those observed in the US (Scotland 47 per 100 000 popula-
tion in 2018, US 23 in 2018). High buprenorphine admission
rates exceeding those in the US were also observed in the Czech
Republic between 2014 and 2017 (56 per 100,000 population and
64, respectively) followed by a steep decline in 2018 (20 per
100 000 population), and in England (20 per 100,000 population
in 2010 vs. 26 2016).
Except for Northern Ireland, rates of “fentanyl, oxycodone or
tramadol” admissions were rather low in Europe. Regarding
tramadol, high treatment admissions rates were observed in North-
ern Ireland between 2014 and 2017 (186–162 per 100,000 popu-
lation). In Scotland rates remained approximately 10 per 100,000
population, and in Ireland rates increased from 03 per 100,000
population in 2010 to 08 in 2018. These were, however, higher than
the tramadol treatment rates observed in the US in 2017 and 2018
(01 per 100,000 population). Regarding fentanyl and oxycodone,
in Scotland, the treatment admissions increased from 01 per
100,000 population in 2015 to 03 in 2018. Importantly, the oxy-
codone admission rates did not reach the extremely high rates seen





























Figure 4e: Buprenorphine Overdose Mortality 

































Figure 4f: Oxycodone Overdose Mortality 
Cyprus The Czech Republic England & Wales France Northern Ireland The US**
Figure 4. (Continued)
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Summary
Again, within Europe Scotland was an outlier with extremely high
opioid treatment admission rates, exceeding those in the US up
until 2017. While the overall rate was relatively stable, shifts
occurred in the contributing drugs. While heroin remained the
largest contributor, it was initially followed by methadone but
ultimately by buprenorphine in 2018. Other European countries
that warrant attention include Ireland and England (very high
heroin rates, relatively high methadone rates), Northern Ireland


























































































Figure 5. Opioid treatment admissions. Different scales are used on the Y-axis. The Y-axis refers to population age, for example, inhabitants aged ≥15 years. In the case of missing
data, the available data points were connected with a line. *Limitations to data coverage resulting in underestimation (see Supplement C for more detailed explanation). (a) Only
outpatient treatments recorded. (b) Overestimate: patients could be counted twice in the database if they received treatment at the same center more than once per calendar year.
(c) Overestimate: all patients in treatment (not treatment admissions). (d) All patients hospitalized in psychiatric hospitals for opioid addiction. (e) Overestimate: all assessments for
treatment.
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Outcome 6: Trends in OST in Europe and the US 2010–2018
Data were available from 19 countries. The rate in most countries
remained relatively stable over the observation period. The highest
OST rates between 2011 and 2018 were in Scotland (555 per
100,000 population in 2018) followed at a distance by the US,
France, Austria, the UK as a whole, and Ireland (Figure 6). Scotland
was the only country with rates higher than those seen in the US in
the same period.
Discussion
The current analysis provides evidence for an increasing trend in
PO consumption in almost all included European countries, with
the largest increase in the UK. Regarding opioid-related adverse
effects there was considerable variation between European coun-
tries.Whilemost countries demonstrated low stable rates of opioid-
related harms, we did identify increases in opioid-related harms in
























































































14 Mimi Pierce et al.
and especially Scotland, however, these increases were not compa-
rable to those in (most states of) the US in the past decade. This is in
line with our assessment 5 years ago, when we concluded that the
risk of an opioid overdose crisis in Europe was small [5].
There are several differences between theUS andEurope thatmay
have prevented the development of an opioid crisis in European
countries. First, marketing of oxycodone directly to patients is often
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Figure 6. Patients in OST. Different scales are used on the Y-axis. The Y-axis refers to population age, for example, inhabitants aged ≥15 years. In the case of missing data, the
available data points were connected with a line. (a) Underestimation due to nonregistration of all patients receiving OST. (b) Data excludes small number of patients receiving OST
with suboxone. (c) An estimate based upon Community Health Index numbers captured on prescriptions. (d) Underestimate because patients prescribed buprenorphine through an
independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility are not
represented in the dataset.
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prescribing and thus increased opioid-related harms in the US,
whereas marketing of drugs directly to patients is prohibited in
Europe [32,33]. Second, while IMF is a serious/dominant problem
in the US, our data suggest that except for Estonia, IMF is not a
problem in Europe [34]. IMF was an important driver of the third
phase of the opioid crisis in the US, because (car)fentanyl is a very
potent opioid with a high abuse liability and because it is regularly
used as an adulterant of heroin and cocaine, or sold as a falsified PO,
resulting in fatal incidents in drug users unaware of the presence of a
highly potent opioid [6]. Third, there are important differences
between the US and Europe in the availability of “street” PO’s (high
diversion and doctor shopping in theUSvs. Europe) [35]. Finally, the
availability of free-of-charge OUD treatments, including OST, is
much lower in the US compared to most European countries [36–
38].
Our current analysis revealed large variations in the opioid
situation within Europe. Most importantly, we observed high PO
consumption in the UK and high and often increasing rates of
opioid-related adverse effects in the British Isles (Scotland, North-
ern Ireland, Ireland, and England). Considering that these coun-
tries share many cultural, socioeconomic, and health care
characteristics, our data suggest a fundamental sociocultural and/or
policy problem in this region. Research and action are warranted to
prevent further escalation of a serious regional opioid crisis on the
British Isles.
Interestingly, we also observed regional differences within the
British Isles. Heroin and methadone were mainly responsible for
opioid-related harms in Scotland and Ireland. In Northern Ireland
mainly synthetic opioids other than methadone (mainly tramadol)
and “other opioids” were most important. In England, a mix of
different opioids were responsible for different opioid-related
harms. These findings call for a multifactorial in-depth analysis
of regional differences in the drivers of the British opioid situation,
including differences in market dynamics related to the availability,
purity, and price of different opioids.
Scotland was consistently an outlier in all our analyses, with the
highest rate of HR opioid users, the highest total opioid-related
hospital admission rates, the second highest opioid treatment
admission rates, the largest number of OST patients, and an
extremely high rate of opioid-related overdose deaths, even exceed-
ing the rate seen in the US. Our findings are in line with the recent
literature suggesting that Scotland currently faces a true opioid
crisis, comparable in magnitude to that in the US [10,39]. The
history, the types of opioids, and the mechanisms involved in the
opioid crisis in these two countries are, however, different. In a
recent study, we concluded that specific drivers for the opioid crisis
in Scotland seem to include frequent polydrug use (opioids com-
binedwith benzodiazepines or gabapentinoids), steeper aging of the
drugs using population in the past two decades, and low treatment
coverage and efficiency in Scotland compared to England/ Wales
[40]. Based on these findings, several recommendations can be
made to further prevent opioid-related problems in Europe, includ-
ing evidence-based guidelines for pain treatment, evidence-based
improvements to establish an efficient addiction treatment system,
and raising awareness about the dangers of combining opioids with
other central depressants [41,42].
Our analysis also revealed some transient increases in opioid-
related harms that reflect the complexity of Europe’s contemporary
drug market, heterogeneity in national regulations and highlight
the importance of early detection and monitoring of opioid supply
chains and availability. In the Czech Republic high buprenorphine
treatment admission rates were observed in 2014, 2015, and 2017
[43]. This local epidemic is attributed to reduced availability of and
waiting lists for buprenorphineOST since 2003, local changes in the
drug scene resulting in increased demand and higher prices of
illegal heroin, and increased availability of illegal and diverted
buprenorphine [43–45]. A second example is Estonia, where we
observed high rates of fentanyl-related mortality peaking in 2017
(nearly reaching the rates observed in the US), in line with the
already observed fentanyl epidemic in Estonia. Fentanyl became the
most commonly used opioid among people who inject drugs in
Estonia between 2000 and 2010, following a severe disruption in
heroin availability due to stricter controls on the Estonian–Russian
border [15,46].
Strengths and limitations
While there have been several articles and reports published about
opioid-related deaths and hospital admission in specific countries
in Europe due to specific opioids, there have been no systematic
data analyses by country or opioid type [47,48]. This is one of the
major strengths of the current study.We used the novel approach of
creating a large database using data from national sources in several
European countries on a broad range of opioid-related topics with a
breakdown per opioid type. In general, however, comparisons
across and within countries were limited by variations in national
methods used and a lack of data fromhalf of all European countries.
Furthermore, our data provided no information about the source of
the opioid involved or the nature of the opioid-related adversity
(e.g., mistaken use of prescription or illicit opioid vs. suicide
attempt).
Regarding our measure of PO consumption, questions remain
about the validity of the INCB data (see Supplement A). Further-
more, although there was a parallel increase in PO consumption
and opioid-related adversities in the UK, this pattern was absent in
other countries, and therefore parallel patterns cannot automati-
cally be interpreted as causal.We also like to note that increased PO
prescribing is not necessarily problematic and may instead be a
reflection of improved pain management. Similarly, an increase in
buprenorphine prescription may indicate improved treatment
access for OUD.
Importantly, our between-country comparisons of opioid-
related hospital admission rates were limited by variation in
definitions. Furthermore, only nonfatal overdose hospital
admissions (primary diagnosis) were included, whereas over-
doses treated by other facilities (e.g., poison information centers)
were not covered. Finally, the growing implementation of Take-
Home Naloxone kits (THN) may have decreased the presenta-
tion of opioid overdoses to hospitals, leading to an underesti-
mation [49].
Our mortality data were difficult to interpret because some
countries have more resources available to conduct toxicological
analyses than others. Even the trends within countries may be
problematic because new technical developments in forensic and
toxicological analyses influence the findings. This is particularly
important for the detection of new emerging highly potent opioids
such as fentanyl and its analogues [50].
While our OST data could be interpreted as a reflection of
the number of opioid dependent patients, it is known that
large variations exist in accessibility and availability and thus
treatment coverage in Europe [51,52]. Finally, while the highest
rates of opioid-related harms were seen in Scotland, Scotland also
had the highest rate of HR opioid users. Future research should
adjust for this potential confounding factor and thus help clarify
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whether the opioid crisis in Scotland is driven by factors causing a
higher prevalence of HR opioid users, factors causing more adverse
effects in each HR opioid user or both.
Conclusions and Recommendations
Apart from the British Isles, and especially Scotland, there appears
to be no evidence for an opioid crisis in the European countries
studied that is similar in magnitude or nature to the crisis in the
US. The long-lasting and ongoing crisis in Britain is likely to be
related to regional socioeconomic and cultural demand issues and
problems in the treatment system. Transient increases in specific
opioid-related problems observed in the Czech Republic and
Estonia are on the other hand more likely to be related to tempo-
rary opioid supply issues, due to changes in the illegal market or a
lack of treatment availability. These trends also reveal the poten-
tial risk of excessive restrictions of POs, whereby a limit in the
supply may lead to a paradoxical rise in substitute use of illicit
opioids. Considering the diversity seen across Europe, our find-
ings call for national and regional actions rather than Europe-wide
strategies to monitor and address opioid-related problems in the
future.
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